MSB Annual Financial Results and Operational Progress
Filed with ASX · · 10 pages · English
In the deck
Earlier from Mesoblast
- Mesoblast Update on Chronic Low Back Pain Program
- MSB Reports Q3 Financial Results and Operational Highlight
- COVID ARDS Trial Topline 60-Day Results
- Mesoblast Raises US$110M Led By US Strategic Investor Group
- Mesoblast Phase 3 Chronic Low Back Pain Results
Later from Mesoblast
- AHA Late-Breaker - Rexlemestrocel Improves Cardiac Outcomes
- MSB and Oaktree Conclude Refinancing of Senior Debt Facility
- Update on Novartis Agreement
- FDAs OTAT Agrees to Primary Endpoint for Back Pain
- Appendix 4C Quarterly Activity Report
Follow Mesoblast into a list and get an email when it puts out news.
Follow Mesoblast